CD44, CD90 and CD96 expression in immune thrombocytopenia purpura (ITP) patients

J Immunoassay Immunochem. 2023 Jul 4;44(4):326-337. doi: 10.1080/15321819.2023.2191259. Epub 2023 Mar 22.

Abstract

Studying the expression of hematopoietic stem cell markers from different sources might be useful in understanding stem cell biology in different niche conditions. The study aimed to assess the difference in cell surface markers (CD44, CD90, CD96) on hematopoietic stem cells in three different niche conditions; umbilical cord blood (UCB), normal bone marrow (NBM) and bone marrow samples from idiopathic (immune) thrombocytopenic purpura (IBM). This study was conducted on 300 cases divided into three study groups; 100 umbilical cord blood units collected from mothers undergoing cesarian section in gynecology and obstetrics department, 100 bone marrow samples from idiopathic (immune) thrombocytopenic purpura patients collected from university children hospital and 100 normal bone marrow samples with no evidence of disease in bone marrow tissue. CD44 was significantly elevated in UCB and NBM groups compared to IBM group (<0.001). There was also a significant elevation of CD90 and CD96 in IBM group compared to NBM group and UCB (<0.001). CD90 and CD96 play a role in the pathogenesis of ITP disorder and could be applied as a targeted therapy to improve the outcome of this disease.

Keywords: CD44; CD90; CD96; IBM; UCB.

MeSH terms

  • Antigens, CD
  • Humans
  • Hyaluronan Receptors
  • Purpura, Thrombocytopenic, Idiopathic* / pathology
  • Thy-1 Antigens / genetics

Substances

  • Antigens, CD
  • CD44 protein, human
  • Hyaluronan Receptors
  • Thy-1 Antigens
  • CD96 antigen